Cell-free and extracellular vesicle microRNAs with clinical utility for solid tumors.

Publication Title

Mol Oncol

Authors

Yoshinori Hayashi, Department of Translational Molecular Medicine, Saint John's Cancer Institute at Providence Saint John's Health Center, Santa Monica, CA, USA.Follow
Janelle-Cheri Millen, Department of Surgical Oncology, Saint John's Cancer Institute at Providence Saint John's Health Center, Santa Monica, CA, USA.Follow
Romela Irene Ramos, Department of Translational Molecular Medicine, Saint John's Cancer Institute at Providence Saint John's Health Center, Santa Monica, CA, USA.Follow
Jennifer A Linehan, Department of Urology and Urologic Oncology, Saint John's Cancer Institute at Providence Saint John's Health Center, Santa Monica, CA, USA.Follow
Timothy G Wilson, Department of Urology and Urologic Oncology, Saint John's Cancer Institute at Providence Saint John's Health Center, Santa Monica, CA, USA.Follow
Dave S B Hoon, Department of Translational Molecular Medicine, Saint John's Cancer Institute at Providence Saint John's Health Center, Santa Monica, CA, USA., Department of Genome Sequencing Center, Saint John's Cancer Institute at Providence Saint John's Health Center, Santa Monica, CA, USA.Follow
Matias A Bustos, Department of Translational Molecular Medicine, Saint John's Cancer Institute at Providence Saint John's Health Center, Santa Monica, CA, USA.Follow

Document Type

Article

Publication Date

8-11-2024

Keywords

california; sjci; santa monica; genomics

Abstract

As cutting-edge technologies applied for the study of body fluid molecular biomarkers are continuously evolving, clinical applications of these biomarkers improve. Diverse forms of circulating molecular biomarkers have been described, including cell-free DNA (cfDNA), circulating tumor cells (CTCs), and cell-free microRNAs (cfmiRs), although unresolved issues remain in their applicability, specificity, sensitivity, and reproducibility. Translational studies demonstrating the clinical utility and importance of cfmiRs in multiple cancers have significantly increased. This review aims to summarize the last 5 years of translational cancer research in the field of cfmiRs and their potential clinical applications to diagnosis, prognosis, and monitoring disease recurrence or treatment responses with a focus on solid tumors. PubMed was utilized for the literature search, following rigorous exclusion criteria for studies based on tumor types, patient sample size, and clinical applications. A total of 136 studies on cfmiRs in different solid tumors were identified and divided based on tumor types, organ sites, number of cfmiRs found, methodology, and types of biofluids analyzed. This comprehensive review emphasizes clinical applications of cfmiRs and summarizes underserved areas where more research and validations are needed.

Area of Special Interest

Cancer

Specialty/Research Institute

Oncology

DOI

10.1002/1878-0261.13709